Unicycive Therapeutics

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Appointment adds decades of drug development experience from a seasoned executive Appointment adds decades of drug development experience from a seasoned executive

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently featured on the Nasdaq Amplify Issuer Spotlight interview series. The series explores how industry leaders within small-cap community are evolving and navigating challenges in various industries.

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies previously announced it would air interviews with 60 Degrees Pharmaceuticals, Inc. and Unicycive Therapeutics, Inc. (Nasdaq:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET).

CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

60 Degrees Pharmaceuticals Inc

ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET).

60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference “Glomerular Disease: IgAN Is Just the Tip of the Iceberg” on Tuesday, July 25, 2023 at 11:00 a.m. ET.

Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

Newly Assigned USAN Name, Oxylanthanum Carbonate, replaces Lanthanum Dioxycarbonate Newly Assigned USAN Name, Oxylanthanum Carbonate, replaces Lanthanum Dioxycarbonate

Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology

Unicycive Therapeutics (NASDAQ: UNCY ) stock is falling on Friday after the medical company provided investors with an update from regulators. According to the clinical-stage biotechnology company, the FDA wants further information concerning lanthanum dioxycarbonate (LDC).

Why Is Unicycive Therapeutics (UNCY) Down 24% Today?

LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today provided an update based on recent interactions with the U.S. Food and Drug Administration (FDA or Agency) concerning the Company's New Drug Application (NDA) for lanthanum dioxycarbonate (LDC), previously known as Renazorb. LDC is an investigational new drug being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program

LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced today that Company CEO, Shalabh Gupta, MD, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET 

Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

ORLANDO, FL / ACCESSWIRE / June 9, 2023 / RedChip Companies will air new interviews with Unicycive Therapeutics, Inc. (Nasdaq:UNCY) and Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 10, at 7 p.m.

Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®

Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

Data highlights the potential safety and reno-protective effect of UNI-494 Data highlights the potential safety and reno-protective effect of UNI-494

Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress

Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones

Unicycive Announces Full Year 2022 Financial Results and Provides Business Update

Bed Bath & Beyond

Tenax Therapeutics

Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Analyzing Penny Stocks After a Market Crash, 3 Tips

FuelCell Energy

Troika Media Group

Use these tips for future proofing your penny stocks strategy The post How to Future Proof Your Penny Stocks Investing Strategy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Future Proof Your Penny Stocks Investing Strategy

Virax Biolabs Group Ltd

What you need to know about day trading penny stocks The post Penny Stocks Investing: The Pros and Cons of Day Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Investing: The Pros and Cons of Day Trading

Novo Integrated Sciences, Inc.

Use these tips for trading penny stocks during market uncertainty The post Penny Stocks Trading: Tips for Market Uncertainty  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Trading: Tips for Market Uncertainty

$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

Data from two abstracts supporting UNI-494's potential to treat acute and chronic kidney injury accepted for presentation at the 28 th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

Develops Renazorb opportunity in new market for patients with hyperphosphatemia

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

Data support UNI-494's potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia Data support UNI-494's potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation's Spring Clinical Meetings

Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the termination of its “at-the-market” equity offering program (the “ATM Offering”) with JonesTrading Institutional Services, LLC as sales agent. The Company elected to terminate the ATM Offering to limit uncertainty and unfavorable dilution for its shareholders.

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol

News for Unicycive Therapeutics Stock (UNCY)